Innovation Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.ipharminc.com
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04784897
- Locations
- 🇷🇺
IPI Investigator Site, Saint Petersburg, Russian Federation
A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04240223
- Locations
- 🇬🇧
BDD Pharma Ltd, Glasgow, Scotland, United Kingdom
A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03042702
- Locations
- 🇺🇸
Cancer Research, Dallas, Texas, United States
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT02949388
- Locations
- 🇺🇸
Study Center, Charlottesville, Virginia, United States
🇺🇸Study Site, Webster, Texas, United States
🇺🇸Clinical Study Site, San Antonio, Texas, United States
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02324335
© Copyright 2024. All Rights Reserved by MedPath